UBS’s Albany Molecular Research Inc AMRI Stock Holding History

UBS’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-500	Closed	-$6K	–	10944
2013 Q2	$6K	Buy	+500	New	+$5.42K	﹤0.01%	9161

Other funds holding AMRI

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

PIP

Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

UBS's AMRI Position: Q3 2014 in Review

UBS sold out of Albany Molecular Research Inc (AMRI) in Q3 2014, closing a stake of 4,645 shares — an estimated $95.1K sold.

UBS first reported a position in AMRI in Q3 2013 and held it in 4 quarters. The position peaked at $93K in Q2 2014. 143 funds tracked by Wall St. Rank hold AMRI as of Q3 2014.

UBS reported no remaining Albany Molecular Research Inc position as of Q3 2014 after selling out during the quarter.
UBS sold 4,645 Albany Molecular Research Inc shares in Q3 2014, an estimated $95.1K.
UBS first reported a position in Albany Molecular Research Inc in Q3 2013 and held it in 4 quarters.
UBS's Albany Molecular Research Inc position peaked at $93K in Q2 2014.
143 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.